BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 32672788)

  • 1. Baicalein suppresses vasculogenic mimicry through inhibiting RhoA/ROCK expression in lung cancer A549 cell line.
    Zhang Z; Nong L; Chen M; Gu X; Zhao W; Liu M; Cheng W
    Acta Biochim Biophys Sin (Shanghai); 2020 Sep; 52(9):1007-1015. PubMed ID: 32672788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of sema4D in vasculogenic mimicry formation in non-small cell lung cancer and the underlying mechanisms.
    Xia Y; Cai XY; Fan JQ; Zhang LL; Ren JH; Li ZY; Zhang RG; Zhu F; Wu G
    Int J Cancer; 2019 May; 144(9):2227-2238. PubMed ID: 30374974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ROCK is involved in vasculogenic mimicry formation in hepatocellular carcinoma cell line.
    Zhang JG; Li XY; Wang YZ; Zhang QD; Gu SY; Wu X; Zhu GH; Li Q; Liu GL
    PLoS One; 2014; 9(9):e107661. PubMed ID: 25238232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [
    An H; Lin J; Sun H; Xu L; Su J; He C; Zeng J; Liang P; He S
    Nan Fang Yi Ke Da Xue Xue Bao; 2018 Jul; 38(8):997-1001. PubMed ID: 30187871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-expressed B7-H3 promotes vasculogenic mimicry formation rather than angiogenesis in non-small cell lung cancer.
    Fan X; Huang J; Hu B; Zhou J; Chen L
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):8729-8741. PubMed ID: 37129607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RhoA/ROCK pathway inhibition by fasudil suppresses the vasculogenic mimicry of U2OS osteosarcoma cells in vitro.
    Xia Y; Cai X; Fan J; Zhang L; Li Z; Ren J; Wu G; Zhu F
    Anticancer Drugs; 2017 Jun; 28(5):514-521. PubMed ID: 28225457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxic induction of vasculogenic mimicry in hepatocellular carcinoma: role of HIF-1 α, RhoA/ROCK and Rac1/PAK signaling.
    Zhang JG; Zhou HM; Zhang X; Mu W; Hu JN; Liu GL; Li Q
    BMC Cancer; 2020 Jan; 20(1):32. PubMed ID: 31931758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between the expression of ARHGAP25 and RhoA in non-small cell lung cancer and vasculogenic mimicry.
    Shi F; Wu J; Jia Q; Li K; Li W; Shi Y; Wang Y; Wu S
    BMC Pulm Med; 2022 Oct; 22(1):377. PubMed ID: 36207695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dickkopf-1-promoted vasculogenic mimicry in non-small cell lung cancer is associated with EMT and development of a cancer stem-like cell phenotype.
    Yao L; Zhang D; Zhao X; Sun B; Liu Y; Gu Q; Zhang Y; Zhao X; Che N; Zheng Y; Liu F; Wang Y; Meng J
    J Cell Mol Med; 2016 Sep; 20(9):1673-85. PubMed ID: 27240974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N6-Isopentenyladenosine Hinders the Vasculogenic Mimicry in Human Glioblastoma Cells through Src-120 Catenin Pathway Modulation and RhoA Activity Inhibition.
    Pagano C; Navarra G; Pastorino O; Avilia G; Coppola L; Della Monica R; Chiariotti L; Florio T; Corsaro A; Torelli G; Caiazzo P; Gazzerro P; Bifulco M; Laezza C
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PP2A regulates metastasis and vasculogenic mimicry formation via PI3K/AKT/ZEB1 axis in non-small cell lung cancers.
    Zhang Y; Wang X; Li A; Guan Y; Shen P; Ni Y; Han X
    J Pharmacol Sci; 2022 Oct; 150(2):56-66. PubMed ID: 36055752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baicalein suppresses growth of non-small cell lung carcinoma by targeting MAP4K3.
    Li J; Yan L; Luo J; Tong L; Gao Y; Feng W; Wang F; Cui W; Li S; Sun Z
    Biomed Pharmacother; 2021 Jan; 133():110965. PubMed ID: 33166766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baicalein suppresses non small cell lung cancer cell proliferation, invasion and Notch signaling pathway.
    Su G; Chen H; Sun X
    Cancer Biomark; 2018; 22(1):13-18. PubMed ID: 29614624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rho kinase mediates transforming growth factor-β1-induced vasculogenic mimicry formation: involvement of the epithelial-mesenchymal transition and cancer stemness activity.
    Zhang X; Zhang J; Zhou H; Liu G; Li Q
    Acta Biochim Biophys Sin (Shanghai); 2020 Apr; 52(4):411-420. PubMed ID: 32296834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rho Kinase Inhibitor Fasudil Suppresses the Vasculogenic Mimicry of B16 Mouse Melanoma Cells Both In Vitro and In Vivo.
    Xia Y; Cai XY; Fan JQ; Zhang LL; Ren JH; Chen J; Li ZY; Zhang RG; Zhu F; Wu G
    Mol Cancer Ther; 2015 Jul; 14(7):1582-90. PubMed ID: 25934709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incarvine C suppresses proliferation and vasculogenic mimicry of hepatocellular carcinoma cells via targeting ROCK inhibition.
    Zhang JG; Zhang DD; Wu X; Wang YZ; Gu SY; Zhu GH; Li XY; Li Q; Liu GL
    BMC Cancer; 2015 Oct; 15():814. PubMed ID: 26510899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombin is a therapeutic target for non-small-cell lung cancer to inhibit vasculogenic mimicry formation.
    Zhao B; Wu M; Hu Z; Ma Y; Qi W; Zhang Y; Li Y; Yu M; Wang H; Mo W
    Signal Transduct Target Ther; 2020 Jul; 5(1):117. PubMed ID: 32647187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ZLDI-8 suppresses angiogenesis and vasculogenic mimicry in drug-resistant NSCLC in vitro and in vivo.
    Lu H; Wu C; Jiang XW; Zhao Q
    Lung Cancer; 2023 Aug; 182():107279. PubMed ID: 37364397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Netrin-1 elicits metastatic potential of non-small cell lung carcinoma cell by enhancing cell invasion, migration and vasculogenic mimicry via EMT induction.
    Zhang X; Cui P; Ding B; Guo Y; Han K; Li J; Chen H; Zhang W
    Cancer Gene Ther; 2018 Feb; 25(1-2):18-26. PubMed ID: 29234153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nrf2 regulates cell motility through RhoA-ROCK1 signalling in non-small-cell lung cancer cells.
    Ko E; Kim D; Min DW; Kwon SH; Lee JY
    Sci Rep; 2021 Jan; 11(1):1247. PubMed ID: 33441941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.